Zymeworks

$39.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.72 (-1.78%) As of 2:32 PM EDT today

Why Robinhood?

You can buy or sell Zymeworks and other stocks, options, and ETFs commission-free!

About ZYME

Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. The listed name for ZYME is Zymeworks Inc.

Employees
256
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
1.83B
Price-Earnings Ratio
Dividend Yield
Average Volume
279.56K
High Today
$41.16
Low Today
$39.86
Open Price
$40.71
Volume
189.99K
52 Week High
$52.75
52 Week Low
$20.33

Collections

ZYME Earnings

-$1.06
-$0.71
-$0.35
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 5, After Hours

You May Also Like